Zai Lab (ZLAB) Assets Average (2017 - 2026)
Zai Lab (ZLAB) posted Assets Average of $1.1 billion for Q1 2026, down 2.71% sequentially from $1.2 billion in Q4 2025, and down 3.86% YoY from $1.2 billion in Q1 2025.
Zai Lab (ZLAB) Assets Average (2017 - 2026) Analysis & Trends
Zai Lab has reported Assets Average for 9 years, with the latest figure at $1.1 billion in Q1 2026.
- Quarterly Assets Average fell 3.86% year-over-year to $1.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 billion (down 3.86% YoY) and the FY2025 annual result came in at $1.2 billion, up 6.12% from the prior year.
- Assets Average declined to $1.1 billion in Q1 2026 per ZLAB's latest filing, from $1.2 billion in the prior quarter.
- Over five years, Assets Average peaked at $1.6 billion in Q1 2022 and troughed at $986.4 million in Q3 2024.
- A 5-year average of $1.2 billion and a median of $1.2 billion in 2025 frame the typical range for Assets Average.
- The widest YoY moves for Assets Average: up 28.08% in 2022, down 25.0% in 2022.
- Over 5 years, Assets Average stood at $1.3 billion in 2022, then declined by 17.42% to $1.0 billion in 2023, then gained by 4.38% to $1.1 billion in 2024, then gained by 7.38% to $1.2 billion in 2025, then slipped by 2.71% to $1.1 billion in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $1.1 billion, $1.2 billion, and $1.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Zai Lab | 2.91 Bn | 2.20 Bn | 58.15 Mn | 1.09 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.09 Bn |
| Mar 31, 2026 | 1.13 Bn |
| Dec 31, 2025 | 1.17 Bn |
| Sep 30, 2025 | 1.16 Bn |
| Jun 30, 2025 | 1.17 Bn |
| Mar 31, 2025 | 1.18 Bn |
| Dec 31, 2024 | 1.09 Bn |
| Sep 30, 2024 | 986.36 Mn |
| Jun 30, 2024 | 987.90 Mn |
| Mar 31, 2024 | 1.01 Bn |
| Dec 31, 2023 | 1.04 Bn |
| Sep 30, 2023 | 1.08 Bn |
| Jun 30, 2023 | 1.14 Bn |
| Mar 31, 2023 | 1.20 Bn |
| Dec 31, 2022 | 1.26 Bn |
| Sep 30, 2022 | 1.36 Bn |
| Jun 30, 2022 | 1.46 Bn |
| Mar 31, 2022 | 1.56 Bn |
| Dec 31, 2021 | 1.67 Bn |
| Sep 30, 2021 | 1.81 Bn |